RELMADA THERAPEUTICS, INC.·4

Jan 31, 6:29 PM ET

TRAVERSA SERGIO 4

4 · RELMADA THERAPEUTICS, INC. · Filed Jan 31, 2024

Insider Transaction Report

Form 4
Period: 2024-01-29
TRAVERSA SERGIO
DirectorChief Executive Officer
Transactions
  • Purchase

    Common Stock

    2024-01-29$3.71/sh+31,541$117,036175,565 total
  • Purchase

    Common Stock

    2024-01-30$3.90/sh+40,999$159,949216,564 total
  • Purchase

    Common Stock

    2024-01-31$4.00/sh+27,460$109,752244,024 total
Footnotes (4)
  • [F1]The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
  • [F2]Purchase prices range from $3.69 to $3.75 per share, inclusive.
  • [F3]Purchase prices range from $3.88 to $3.97 per share, inclusive.
  • [F4]Purchase prices range from $3.95 to $4.05 per share, inclusive.

Documents

1 file
  • 4
    ownership.xmlPrimary